There is on-going development of generic EU CTD Dossier of Levofloxacin hemihydrate, 250/500 mg, filmcoated tablets.
Development of this pharmaceutical is carried out according to EU-requirements in country without patent protection or with Bolar-provisions. There will be no sales in those countries where this offer would constitute an infringement of third parties intellectual proprietary rights.
Levofloxacin is a synthetic chemotherapeutic agent used to treat severe or life threatening bacterial infections. It is sold under various brand names, such as Levaquin and Tavanic, the most common. In form of ophthalmic solutions it is known as Oftaquix, Quixin and Iquix. Levofloxacin belongs to the class of fluoroquinolone (or quinolone) antiinfectives.
Chemically, levofloxacin is a chiral fluorinated carboxyquinolone. Investigation of ofloxacin, an older drug that is the racemic mixture, found that the l form [the (-)-(S) enantiomer] is more active. This specific component is levofloxacin.
Levofloxacin interacts with a number of other drugs, as well as a number of herbal and natural supplements. Such interactions increase the risk of cardiotoxicity and arrhythmias, anticoagulation, the formation of non-absorbable complexes, as well as increasing the risk of toxicity.
More details at: http://www.rxlist.com/levaquin-drug.htm
|Pharma licensing||Out-licensing (offer)|